- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00538187
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
Phase I Study of GX15-070 (NSC # 729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma
Visão geral do estudo
Status
Condições
- Linfoma Adulto Difuso de Células Grandes Recorrente
- Linfoma Folicular Grau 1 Recorrente
- Linfoma folicular de grau 2 recorrente
- Linfoma folicular recorrente de grau 3
- Linfoma de Células do Manto Recorrente
- Linfoma de Zona Marginal Recorrente
- Linfoma linfocítico pequeno recorrente
- Linfoma Não Hodgkin Adulto
Descrição detalhada
PRIMARY OBJECTIVES:
I. To establish the maximum tolerated dose of obatoclax mesylate when administered with bortezomib in patients with aggressive relapsed or recurrent non-Hodgkin lymphoma.
II. To describe the toxicities of this regimen at each dose studied in these patients.
III. To characterize the pharmacokinetic behavior of this regimen in these patients.
IV. To obtain preliminary information regarding the effect of obatoclax mesylate on several apoptotic regulatory pathways.
V. To document all clinical responses in these patients to this regimen.
OUTLINE: This is a multicenter study.
PHASE I: Patients receive obatoclax mesylate IV over 3 hours followed by bortezomib IV on days 1, 8, 15, and 22.
Treatment repeats every 35 days in the absence of disease progression or unacceptable toxicity. Pharmacokinetic evaluations of obatoclax mesylate are conducted in all patients during the first course.
PHASE II: Patients receive obatoclax mesylate IV over 3 hours followed by bortezomib IV on days 1, 8, 15, and 22 at the maximum tolerated dose determined in phase I.
Treatment repeats every 35 days for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 26 weeks.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Histologically or cytologically confirmed relapsed or refractory non-Hodgkin lymphoma for which standard curative or palliative measures do not exist or are no longer effective, including any of the following subtypes:
- Follicular grade I, II, or III lymphoma
- Marginal zone lymphoma
- Mantle cell lymphoma
- Diffuse large B cell lymphoma
- Small lymphocytic lymphoma
Must have had at least one prior chemotherapeutic regimen:
- Steroids or rituximab alone or local radiotherapy do not count as regimens
- Tositumomab or ibritumomab tiuxetan allowed as regimens
- Clear evidence of disease progression or lack of response after the most recent therapy, including rituximab or local radiotherapy, is required
- At least 3 months since prior autologous stem cell transplantation and relapsed (>= 1 year since prior allogeneic transplantation and relapsed) and no active related infections (i.e., fungal or viral)
- In the case of allogeneic transplantation relapse, there should be no active acute graft-versus-host disease (GVHD) of any grade and no chronic GVHD other than mild skin, oral, or ocular GVHD not requiring systemic immunosuppression
- No known active brain metastases, other neurological disorders/dysfunction or history of seizure disorder, or other neurological dysfunction
- Karnofsky performance status 60-100%
- Life expectancy > 3 months
- Total bilirubin normal
- AST and ALT =< 2.5 times upper limit of normal
- Creatinine normal or creatinine clearance >= 60 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-barrier contraception during and for 3 months after the last dose of obatoclax mesylate
- At least 4 weeks since prior radiotherapy
- More than 2 days since prior steroids
- More than 2 weeks since prior low-dose chlorambucil
- WBC >= 3,000/mm^3
- ANC >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- At least 2 weeks since prior valproic acid
Exclusion Criteria:
Uncontrolled concurrent medical condition or illness including, but not limited to, any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia including QTc > 450 msec
- Patients who are intolerant or refractory to prior treatment with bortezomib (refractory is defined as no response to prior treatment with bortezomib)
- Chemotherapy within the past 4 weeks (6 weeks for nitrosoureas or mitomycin C)
- Rituximab within the past 3 months (unless there is evidence of progression)
- Patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Other concurrent investigational agents
- Combination antiretroviral therapy for HIV-positive patients
- No history of allergic reactions attributed to bortezomib, polyethylene glycol (PEG 300), or polysorbate 20
- No psychiatric illness or social situation that would limit compliance with study requirements
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment (obatoclax mesylate, bortezomib)
Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
|
Dado IV
Outros nomes:
estudo correlativo
Outros nomes:
estudo correlativo
Dado IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Maximum tolerated dose of obatoclax mesylate when administered with bortezomib
Prazo: 35 days
|
Defined as the highest dose tested in which fewer than 33% of patients experienced DLT attributable to the study drug(s), when at least six patients were treated at that dose and are evaluable for toxicity.
Graded according to the NCI CTCAE, Version 3.0.
|
35 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Toxicity as assessed by NCI CTCAE version 3.0
Prazo: Up to 26 weeks after completion of study treatment
|
Summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity and nadir or maximum values for the laboratory measures, time of onset (i.e.
course number), duration, and reversibility or outcome.
Tables will be created to summarize these toxicities and side effects by dose and by course.
|
Up to 26 weeks after completion of study treatment
|
Pharmacokinetics of obatoclax mesylate when administered with bortezomib
Prazo: Dose 1 of course 1, pre-infusion, 1 and 2 hours into the infusion, immediately prior to the end of the infusion, then at 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 168 hours
|
Dose 1 of course 1, pre-infusion, 1 and 2 hours into the infusion, immediately prior to the end of the infusion, then at 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 168 hours
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Joseph Tuscano, City of Hope Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Processos Patológicos
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias
- Distúrbios Linfoproliferativos
- Doenças Linfáticas
- Distúrbios imunoproliferativos
- Atributos da doença
- Leucemia Linfóide
- Leucemia
- Leucemia de Células B
- Linfoma de Células B
- Linfoma
- Linfoma Folicular
- Linfoma de Células B Grandes Difuso
- Recorrência
- Linfoma Não-Hodgkin
- Linfoma de Células do Manto
- Leucemia Linfocítica Crônica de Células B
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Bortezomibe
- Obatoclax
Outros números de identificação do estudo
- NCI-2009-00253
- U01CA062505 (Concessão/Contrato do NIH dos EUA)
- PHI-58
- CDR0000566357
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em bortezomibe
-
Virginia Commonwealth UniversityConcluídoMelanoma | Sarcoma de Partes Moles | Carcinoma de Paratireoide | Carcinoma de Pequenas Células do Pulmão | Tumores CarcinoidesEstados Unidos
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium Pharmaceuticals, Inc.ConcluídoCâncer de Cabeça e Pescoço | Neoplasias do Sistema Nervoso Central | Cancer cerebral | Câncer de colo do úteroEstados Unidos
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's Hospital; Millennium...ConcluídoLinfoma Linfoplasmocítico | Macroglobulinemia de WaldenstromEstados Unidos
-
University of ArkansasMillennium Pharmaceuticals, Inc.RescindidoMieloma múltiploEstados Unidos
-
Assistance Publique - Hôpitaux de ParisConcluídoEficácia do Bortezomib (Velcade(R)) em pacientes com macroglobulinemia de Waldenström avançada (WM2)Waldenstrom MacroglobulinemiaFrança
-
Mayo ClinicNational Cancer Institute (NCI)ConcluídoLeucemia | Distúrbios Mieloproliferativos CrônicosEstados Unidos
-
Millennium Pharmaceuticals, Inc.ConcluídoCarcinoma ColorretalEstados Unidos
-
Millennium Pharmaceuticals, Inc.RescindidoCâncer Avançado de Pulmão de Células Não Pequenas | Outros Tumores Sólidos
-
The First Affiliated Hospital of Soochow UniversityDesconhecidoMieloma Múltiplo Comprovado por Exames LaboratoriaisChina